Article
Optimized AAV capsids for diseases of the basal ganglia show robust potency and distribution in adult nonhuman primates
2024-05-05
Abstract excerpt
Huntington’s disease and other disorders of the basal ganglia create challenges for biomolecule-based medicines given the poor accessibility of these deep brain structures following intracerebral or intravascular delivery. Additionally, for adeno-associated viruses (AAVs) intravascular delivery exposes peripheral tissues to the vast majority of the therapy, increasing the risk of immune responses and the quantity...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 05e24cde-876d-50ab-94db-e820a004c003
- DOI
- 10.1101/2024.05.02.592211
